However, CML clones expressing BCR::ABL1 T315 show decreased proliferation upon palbociclib treatment underlining the role of CDK6 in this disease context and suggesting that suppression of CDK4/CDK6 may be a promising concept to overcome BCR::ABL1 T315I-associated TKI resistance [52]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.